AR122352A1 - Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este - Google Patents
Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de esteInfo
- Publication number
- AR122352A1 AR122352A1 ARP200103421A ARP200103421A AR122352A1 AR 122352 A1 AR122352 A1 AR 122352A1 AR P200103421 A ARP200103421 A AR P200103421A AR P200103421 A ARP200103421 A AR P200103421A AR 122352 A1 AR122352 A1 AR 122352A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- pyrazolil
- disubstituted
- steroid
- subject
- Prior art date
Links
- VVUQRXPUVKXAIO-XFUVECHXSA-N 19-nor-5-androstenediol Chemical compound C1[C@@H](O)CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 VVUQRXPUVKXAIO-XFUVECHXSA-N 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En el presente documento se proporcionan métodos para tratar la depresión, tal como el trastorno depresivo mayor, en un sujeto que lo necesite, que comprenden la administración al sujeto de una cantidad eficaz del compuesto de fórmula (1) o de una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944144P | 2019-12-05 | 2019-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122352A1 true AR122352A1 (es) | 2022-09-07 |
Family
ID=74106152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200103421A AR122352A1 (es) | 2019-12-05 | 2020-12-09 | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230018765A1 (es) |
| EP (1) | EP4069250A1 (es) |
| JP (1) | JP2023504517A (es) |
| KR (1) | KR20220112803A (es) |
| CN (1) | CN114761019A (es) |
| AR (1) | AR122352A1 (es) |
| AU (1) | AU2020395246A1 (es) |
| CA (1) | CA3163556A1 (es) |
| IL (1) | IL293510A (es) |
| MX (1) | MX2022006533A (es) |
| TW (1) | TW202133863A (es) |
| WO (1) | WO2021113786A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| MX2015002252A (es) | 2012-08-21 | 2015-07-21 | Sage Therapeutics Inc | Metodos para tratar epilepsia o estado de epilepsia. |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3719029A1 (en) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions for inducing sedation |
| CN115974955A (zh) | 2016-08-23 | 2023-04-18 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体 |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX362543B (es) * | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| IL303250A (en) * | 2017-09-07 | 2023-07-01 | Sage Therapeutics Inc | Neuroactive steroids and their methods of use |
| WO2019055764A1 (en) * | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | C21-N-PYRAZOLYL C3,3-DISUBSTITUTED STEROID 19 NOR, AND METHODS OF USING THE SAME |
| MA51568A (fr) * | 2018-01-12 | 2021-04-21 | Sage Therapeutics Inc | Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central |
| EP3806863A1 (en) * | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
-
2020
- 2020-12-05 CN CN202080084566.0A patent/CN114761019A/zh active Pending
- 2020-12-05 WO PCT/US2020/063507 patent/WO2021113786A1/en not_active Ceased
- 2020-12-05 IL IL293510A patent/IL293510A/en unknown
- 2020-12-05 US US17/782,362 patent/US20230018765A1/en not_active Abandoned
- 2020-12-05 EP EP20834042.2A patent/EP4069250A1/en not_active Withdrawn
- 2020-12-05 KR KR1020227022451A patent/KR20220112803A/ko active Pending
- 2020-12-05 CA CA3163556A patent/CA3163556A1/en active Pending
- 2020-12-05 JP JP2022533122A patent/JP2023504517A/ja active Pending
- 2020-12-05 AU AU2020395246A patent/AU2020395246A1/en active Pending
- 2020-12-05 MX MX2022006533A patent/MX2022006533A/es unknown
- 2020-12-07 TW TW109143121A patent/TW202133863A/zh unknown
- 2020-12-09 AR ARP200103421A patent/AR122352A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230018765A1 (en) | 2023-01-19 |
| KR20220112803A (ko) | 2022-08-11 |
| AU2020395246A1 (en) | 2022-06-16 |
| EP4069250A1 (en) | 2022-10-12 |
| MX2022006533A (es) | 2023-03-01 |
| IL293510A (en) | 2022-08-01 |
| TW202133863A (zh) | 2021-09-16 |
| CA3163556A1 (en) | 2021-06-10 |
| WO2021113786A1 (en) | 2021-06-10 |
| CN114761019A (zh) | 2022-07-15 |
| JP2023504517A (ja) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122352A1 (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| AR134548A2 (es) | Compuesto esteroide neuroactivo | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
| MX2025000166A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| CL2020002915A1 (es) | Composiciones para el tratamiento de condiciones de la piel | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CL2019003393A1 (es) | Virus oncolíticos y método. | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| CL2019002340A1 (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
| CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| MX2021005751A (es) | Anticuerpos contra mucina 16 y métodos de uso de los mismos. | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| CL2023003841A1 (es) | Trampas de ligando del factor de crecimiento transformante beta para el tratamiento de enfermedades | |
| ECSP13012524A (es) | Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia |